The company’s pipeline looks intriguing, but everything is still preclinical. In a normal biotech market, an IPO would probably be considered premature.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.